HR070803

HR070803 is a small-molecule drug developed by Jiangsu HengRui Medicine. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. The sponsor states: Identified on the trial page as an irinotecan liposome formulation (pharmacokinetics tracked via the active metabolite SN-38 and parent compound CPT-11), given intravenously in combination with oxaliplatin, 5-FU/leucovorin and bevacizumab as first-line therapy for metastatic colorectal cancer. ClinicalTrials.gov describes the intervention as: HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 8-12 cycles, and then ente. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT05945901 (A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer), in colorectal cancer. The largest, NCT05945901, plans to enrol 669 participants (actual) with primary completion was scheduled for 2025-12-01 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.